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Induction of stable chimerism and elimination 
of graft-versus-host disease by depletion of T 
lymphocytes from bone marrow using 
immunomagnetic beads 
A. L. Hoffman, MD, L. Makowka, MD, PhD, D. V. Cramer, DVM, PhD, X. Cai, MD, 
B. Banner, MD, A. Pascualone, MD, S. Hoffmann, BS,and T. E. Starzl, MD, PhD, 
Pittsburgh, Pa. 
The goal of transplantation is the induction of immunologic tolerance. At present, 
nonspecific immunosuppression is used to prevent graft rejection and, commonly, 
graft-versus-host disease (CVHD). Nevertheless, nonspecific immunosuppressive 
therapy is frequently complicated by infection, malignant tumors, and drug toxicity. In 
order to examine whether hematopoietic chimerism can be used to induce specific 
allograft tolerance, we have reconstituted lethally irradiated Lewis rats with ACI bone 
marrow that has been depleted of T cells with use of immunomagnetic beads. This 
technique consists of binding OX-19, a mouse anti-rat pan- T lymphocyte monoclonal 
antibody, to magnetic polymer beads. Mixing of bone marrow or splenocytes with the 
bead/OX-79 complexes, followed by magnetic separation, results in significant 
depletion of T cells with minimal nonspecific cell loss. Immunomagnetic T-cell 
depletion of bone marrow, followed by reconstitution of a lethally irradiated host, allows 
for the development of stable, mixed hematopoietic chimerae without evidence of 
CVHD. These hosts are immunocompetent by clinical criteria. Recipients of untreated 
donor bone marrow that did or did not receive nonspecific immunosuppression 
demonstrated varying degrees of CVHD and reduced survival. The ability to rapidly 
and simply deplete T lymphocytes from bone marrow and produce stable, 
immunocompetent hematopoietic chimerae without CVHD may be an important 
method for tolerance induction to vascularized allografts. (SURGERY 1989;106:354-63.) 
From the Departmepts of Surgery and Pathology, University of Pittsburgh Health Center, 
University of Pittsburgh, Pittsburgh, Pa. 
THE SUCCESSFUL INDUCTION of specific tolerance con-
tinues to be an elusive goal in the postoperative 
treatment of patients after organ transplantation. 
Despite the use of a variety of techniques, there has been 
no conclusive evidence supporting the achievement of a 
permanent state of tolerance to vascularized organs in 
human beings. At present, the control of allograft rejec-
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tion depends on the use of nonspecific immunosuppres-
sive agents, which induce a generalized paralysis of the 
immune system and predispose the recipient to the 
development of secondary infections.t, 2 
It has recently been demonstrated that the induction 
of hematopoietic chimerism, after bone marrow trans-
plantation in the mouse, is associated with the develop-
ment of a specific tolerance to donor skin allografts and 
xenografts.3 In order to establish whether hematopoie-
tic chimerism is capable of inducing tolerance to vascu-
larized organ allografts, we have begun a series of ex-
periments that examine the influence of chimerism on 
immunologic tolerance in rats. The rat represents a 
more suitable model than the mouse in which to study 
the rejection process of vascularized organ allografts. In 
preliminary studies we have demonstrated the preven-
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Fig. 1. Immunomagnetic bead preparation. A, Step 1: Monosized magnetic beads bound with sheep anti·mouse 
IgG are incubated with fetal calf serum to prevent nonspecific depletion of bone marrow cells. B, Step 2: The beads 
are then mixed with OX-19, a mouse anti-rat monoclonal antibody specific for rat T lymphocytes and thymo-
cytes. 
tion of graft-versus-host disease (GVHD) with use of 
immunomagnetic T-Iymphocyte depletion (ITLD) in a 
rat model.4 This report demonstrates the usefulness of 
ITLD to induce stable chimerism after bone marrow 
transplantation between fully allogeneic, strongly histo-
incompatible donor-recipient strain combinations. 
MATERIAL AND METHODS 
Animals. The animals used were 200 to 300 gm 
inbred male ACI (R T1 a) and Lewis (R T11) strain rats 
purchased from Harlan Sprague Dawley (Indianapolis, 
Ind.). They were given acidified water containing 
tetracycline hydrochloride (100 mg/L) and neomycin 
sulfate (10 mg/L) and fed rat food (Wayne Lab Blox 
F-6, Chicago, Ill.) ad libitum. The rats were allowed to 
acclimatize to the conventional facility for 2 weeks 
before experimentation. 
Immunomagnetic bead preparation. The initial 
step of bead preparation was performed as previously 
described.5 Magnetic, monosized polymer beads (20% 
magnetite by weight) are commercially available with 
covalently bound, affinity-purified sheep anti-mouse 
IgG directed against all mouse IgG subclasses (M450-
11001, Dynal-Dynabeads, Great Neck, N.Y.). The 
beads were incubated with 1 0 ~l of fetal calf serum 
(FCS) per mg of beads for 24 hours at 40 C, and washed 
three times with Hanks' balanced salt solution (HBSS) 
(Fig. 1, A). Then, OX-19, a mouse anti-rat pan-T 
lymphocyte monoclonal antibody, was mixed with the 
immunomagnetic beads at 1 ~l/mg bead. The incuba-
tion conditions were the same as described above 
(Fig. 1, B). 
T-Lymphocyte depletion of bone marrow. Donor 
bone marrow was depleted of T lymphocytes by means 
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Fig. 2. T-Lymphocyte depletion of rat bone marrow. A, Step 1: The beadjOX-19 complexes are mixed with 
ACI bone marrow, and binding of the antibody results in rosette formation. B cells, stem cells, and other pro-
genitor cells remain in solution. B, Step 2: The beadjOX-19 jT -cell complexes are polarized toward an applied 
magnetic force. The supernatant (containing B cells, stem cells, and other progenitor cells) is easily removed. 
of immunomagnetic bead/OX-19 complexes. Bone 
marrow was harvested from the tibias and femurs of 
ACI rats by a previously described technique.6 Cell 
counts and viability were determined by trypan blue 
exclusion, and the viability of the cell suspensions 
always exceeded 90%. The bone marrow was mixed 
with the OX-19-coated beads in 5 to 10 ml of HBSS 
containing 0.05 mg/ml of gentamicin in a round-
bottomed glass test tube (Fig. 2, A) and incubated at 
room temperature for 30 minutes. Gentle mixing was 
performed six times during the incubation. Magnetic 
separation was accomplished with a cobalt-samarium 
magnet. The bead/OX-19 /T -lymphocyte complexes 
were polarized to the magnet and immobilized against 
the test tube wall (Fig. 2, B). The supernatant-
containing stem cells, progenitor cells, and B cells-was 
. extracted and used.for flow cytometric analysis or bone 
marrow transplantation. 
Spleen preparation. The spleens of ACI strain rats 
were removed after rats were killed by CO2 asphyxia-
tion. The spleen cells were prepared by mincing the 
organ in RPM I solution. Splenocytes were isolated, 
counted, and viability established by trypan blue exclu-
sion technique. 
Flow cytometry. The analysis of cell surface-asso-
ciated markers by flow cytometry was conducted by 
placing 1 X 106 bone marrow or spleen cells ( ± ITLD) 
in 12 X 75 mm glass tubes in 0.1 ml of staining buffer 
(phosphate buffered saline solution, pH 7.4, 0.1% Na-
azide, 2% FCS). The marker antisera (OX-19) or 
normal sera were added (1:10 to 1:100 final dilution) for 
30 minutes at 40 C. The cells were washed twice and 
resuspended in fluoroscein isothiocyanate-Iabeled anti-
IgG directed against the primary antibody (rat anti-
mouse IgG, Hand L chain specific; Boehinger-Mann-
heim, Indianapolis, Ind.). After a 30-minute incubation 
period at 4 0 C, the cells were washed twice and analyzed 
for fluorescent staining in a flow cytometer (F AC-
STAR, Becton-Dickinson, Mountain View, Calif.). 
Bone marrow reconstitution. Total body irradia-
tion (1000 rad) was administered to recipient rats 4 to 
6 hours before bone marrow reconstitution. Induction of 
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Table I. Treatment groups 
Group n 
I 10 
II 20 
III 10 
IV 10 
V 10 
VI 10 
Donor 
ACI 
ACI 
ACI 
ACI 
ACI 
Legend: BMTx, Bone marrow transplantation. 
·For doses, see text. 
Recipient 
Lewis 
Lewis 
Lewis 
Lewis 
Lewis 
Lewis 
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Pre-BMTx 
host Rx 
(rad) AI' 
1000 
1000 
1000 
1000 
1000 
1000 
BM 
treatment 
ITLD 
Post BMTx* 
host treatment 
FK-506 
CyA 
FK-506 + CyA 
Table n. Chimerism induction and prevention of graft-versus-host disease in lethally irradiated Lewis rats 
BM Host 
Group n Donor Rx Rx 
10 
II 20 ACI 
III 10 ACI ITLD 
IV 10 ACI FK-506 
V 10 ACI CyA 
VI 10 ACI FK-506 + 
CyA 
'x2 test. 
tSurvival at 90 days; Cox-Mantel test. 
;p < 0.05. 
§p < 0.001. 
anesthesia was performed by intraperitoneal injection of 
3.6% chloral hydrate. An upper midline celiotomy was 
performed. The intestines were eviscerated and re-
tracted toward the left upper quadrant. A total of 
50 X 106 bone marrow cells from ACI rats (±ITLD), 
suspended in 1.5 ml of HBSS containing 0.05% gen-
tamicin, was injected into the exposed infrahepatic vena 
cava above the renal veins. Hemostasis was ensured, and 
the viscera were restored to their normal intra-abdom-
inal position. The fascia and skin were closed in two 
layers with 4-0 polyglycolic acid (Dexon) suture. This 
method of bone marrow inoculation through the ex-
posed inferior vena cava was used to provide the appro-
priate controls for experiments involving the placement 
of intra-abdominal vascularized allografts. 
Drug immunosuppression. Two drugs, FK-506 
and cyclosporine (CyA), were used to produce nonspe-
cific immunosuppression. 
FK-506, generously supplied in powder form by Fu-
jisawa Pharmaceutical Company, Ltd., Osaka, Japan, 
was reconstituted in normal saline solution. The drug 
was administered orally at 0.5, 1.6, and 3.2 mg/kg on 
BM Clin. Hist. Surv 
engrajt* GVHD* GVHD at QOdt Chimerism 
0/0 No 
11/20 11/11 ++ 0/20 N/A 
10/10* 0/10§ 0 1O/10§ Yes; stable 
9/10 
9/10 
9/10 
0/9§ + 1/10 Yes; 2 rno 
0/9§ + 0/10 N/A 
0/9§ + 0/10 Yes; 2 rno 
only 
days 0 to 28 using an No. 14 gauge feeding gavage 
catheter. When used in a two-drug regimen, the FK-506 
was used at 0.5 mg/kg/day and CyA at 5.0 mg/kg/day. 
CyA was generously supplied by the Sandoz Phar-
maceutical Corporation, East Hanover, N.J. The liquid 
form (100 mg/ml) was mixed with olive oil and admin-
istered at 5.0 mg/kg/day through a No. 14 feeding gav-
age catheter 3 hours after the administration of FK-506 
(0.5 mg/kg/day only). When used alone, the powder 
form of Cy A was mixed in a Miglyol base to a concen-
tration of 25 mg/ml and administered in a deep intra-
muscular depot at a dose of 25 mg/kg/ day from days -1 
to 18. 
In vivo comparison of ITLD versus nonspecific 
immunosuppression (Table I). All hosts were Lewis 
strain rats that had received toOO rad of total body ir-
radiation. Group I received no bone marrow reconsti-
tution. Groups II and IV through VI received untreated 
ACI bone marrow. Group III received ITLD-treated 
ACI bone marrow. Group IV received oral FK-506 at 
1.6 mg/kg/day (n = 5) or 3.2 mg/kg/day (n = 5) from 
days 0 to 28. Group V received CyA 25 mg/kg/day in-
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Fig. 3. Single-color How cytometric assessment of T -lymphocyte depletion. A, Bone marrow: With 20 beads per 
T cell, ACI bone marrow is depleted to a 1 % T-cell population from the control levels of 9.4%. B, Spleen: Lym-
phocytes in ACI spleen account for 40.9% of its lymphocyte population. Following the same conditions as in A, 
ITLD results in a depletion of T lymphocytes to 1.3%. 
tramuscularly from days -1 to 18. Group VI received 
oral FK-S06 (0.5 mg/kg/day) and oral eyA (5.0 mg/ 
kg/day) from day 0 through 28. 
Assessment of chimerism. The presence of hem-
atopoietic chimerism was established with a hemagglu-
tination assay for the expression of donor MHC class I 
histocompatibility antigens. Lewis anti-ACI antisera to 
RT1.A histocompatibility antigens was used in a stan-
dard hemagglutination protocoP Red cell chimerism 
was assessed by the demonstration of donor erythrocytes 
in the peripheral blood of animals surviving longer than 
2 months. The levels of chimerism were estimated by 
comparison to control experiments in which erythro-
cytes from the donor and recipient strains were mixed 
in 10% ratios from 0% to 100% each and then tested for 
hemagglutination. 
Assessment of GVHD. The recipients of donor bone 
marrow were assessed for GVHD on a daily basis. Rats 
were weighed every 2 to 3 days. The diagnosis of 
GVHD was based on previously described clinical and 
histopathologic findings. 6, 8, 9 An animal was considered 
to exhibit acute GVHD if at least four of the following 
signs were observed: diffuse erythema, hyperkeratosis of 
the foot pads, dermatitis, weight loss, generalized 
unkempt appearance, or diarrhea. Necropsy specimens 
from the non-ITLD groups were taken from the ear, 
tongue, liver, spleen, small intestine, and mesenteric 
lymph nodes. Five ear biopsy specimens from the ITLD 
group taken on day 34 were also examined. The spec-
imens were processed routinely for light microscopy, 
with use of hematoxylin-eosin staining, and examined 
for the histopathologic features associated with acute 
GVHD.8,9 
Statistics. Survival data were compared with Kap-
lan-Meier plots using a generalized Savage (Cox-
Mantel) test. The incidence of engraftment and GVHD 
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Fig. 4. Photomicrographs of an ear of a lethally irradiated Lewis rat. A, Recipient of untreated ACI bone mar-
row (25 days after reconstitution). Single cell necrosis in basal layers of epithelium (arrow) and mononuclear 
cell infiltrate. (Hematoxylin and eosin stain. Original magnification X160.) B, Recipient of ITLD-treated ACI 
bone marrow (34 days after reconstitution). Normal ear skin. (Hematoxylin and eosin stain. Original magnifi-
cation X 160.) 
within respective groups was compared by X2 analysis. 
A value of p < 0.05 was considered statistically signif-
icant. 
RESULTS 
T -Lymphocyte depletion of bone marrow. Flow 
cytometry of both spleen and bone marrow was used to 
test the effectiveness of the lTLD technique. Normally, 
rat bone marrow contains approximately 5% to 6% of its 
lymphocyte population as T cells, and rat spleen, 
approximately 50%. Various bead/T lymphocyte ratios 
were examined (1:1, 2:1, 5:1, 20:1, 60:1) to determine 
satisfactory depletion with minimal nonspecific cell loss. 
ITLD (20 beads:l T cell) of ACI bone marrow reduced 
the population at T cells from 9.4% to 1.0% most effi-
ciently (Fig. 3, A). With this same ratio, the ACI spleen 
T -lymphocyte population was decreased from 40.3% to 
1.3% (Fig. 3, B). Nonspecific cell 'loss after ITLD was 
in the range of2% to 9%. Less than a 20:1 bead/T lym-
phocyte ratio resulted in inefficient removal of T cells. 
A 60:1 bead/T lymphocyte ratio was associated with a 
31 % nonspecific cell depletion. 
In vivo assessment ofT-lymphocyte depletion. All 
10 lethally irradiated control Lewis rats that did not 
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Fig. 5. A, Microscopic section of liver: R ecipient of untreated ACI bone marrow. Note the presence or lympho-
cytes and single cell necrosis in the bile duct epithelium (anow) . (Hematoxylin and eosin stain. Original mag-
nification Xl00.) B, Microscopic section of spleen : Recipient of untreated ACI bone marrow . Note depletion of 
lymph ocytes in periartcrior sheath (arrow) . Infiltration of mantle zone (right half of photo) by primitive cells and 
megakaryocytes (m) , indica ting repopulation by marrow elements and possible GVHD. 
receive bone marrow reconstitution (Tab'le II; group I) 
died, as expected, by day 13. Eleven rats irradiated and 
reconstituted with untreated ACI bone marrow, all had 
clinical signs of acute GVHD (group II). Of these an-
imals, 9 of 11 were dead by day 25, and the remaining 
two rats died by 48 days with clinical and pathologic 
lesions consistent with acute GVHD. 
The most common manifestation of clinical acute 
GVHD was erythema of the ears. The most specific 
clinical determinant appeared to be the combination of 
erythema, hyperkeratosis of the foot pads, and severe 
weight loss. The most consistent and sensitive histo-
pathologic lesion of acute GVHD in these animals was 
the appearance of single basal epithelial cell necrosis 
with adjacent lymphocyte infiltration (satellitosis) in the 
tongue and ear (Fig. 4, A). The ear was unaffected in 
rats receiving nonspecific immunosuppression. The 
livers of affected animals frequently exhibited lympho-
cytic infiltration of the portal triads, with injury to the 
bile duct epithelium ranging from disorganization with 
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Fig. 6. Postoperative weight change after bone marrow transplantation. Only those animals receiving ITLD-
treated ACI bone marrow gained weight and survived as long-term stable chimerae. All animals in control and 
other treatment groups lost weight and died within 90 days, except for a single recipient receiving FK-506. 
focal cellular injury to complete destruction and satel-
litosis (Fig. 5, A). Other histopathologic features 
included lymphocytic depletion of lymph node paracor-
tical areas and splenic arteriolar sheaths, with lympho-
blast or histocyte infiltration of the mantle zone and ex-
tramedullary hematopoiesis (Fig. 5, B). Cryptitis was 
present in sections of the small intestine. 
Ten lethally irradiated Lewis rats received ACI bone 
marrow treated with ITLD (group III). There was 
successful engraftment in all animals and 100% survival 
for more than 165 days. No clinical or histopathologic 
evidence for acute or chronic GVHD was present 
during any period of their posttransplant course. The 
recipients of ITLD-treated ACI bone marrow had nor-
mal ear biopsy specimens at 34 days after transplanta-
tion (Fig. 4, B). The recipient rats that received 
nonspecific immunosuppression in the postoperative 
period (groups IV through VI) did not develop clinical 
signs of acute GVHD. In some animals in all three 
groups, however, mild histologic evidence of GVHD 
developed, and the survival in the three groups was poor, 
with all but one animal dead by 90 days. There was no 
apparent difference between FK 1.6 mg/kg/ day and 3.2 
mg/kg/day. 
All of the recipients of ITLD-treated marrow gained 
weight by day 7. This progressed steadily, and 10 
months after bone marrow transplantation, the chime-
rae not used in other experimental protocols had gained 
100% of their body weight. All of the recipients in the 
Table m. Erythrocyte chimerism in lethally 
irradiated Lewis rats receiving ITLD-treated ACI 
bone marrow: Hemagglutination assay 
% Chimerism 
100 
90 
80 
70 
60 
50 
40 
30 
20 
10 
o 
4 mo 
2 
No. of chimeric rats 
7mo 
1 
2 
2 
11 mo 
2 
control and other treatment groups lost weight and died, 
except for a single rat in group IV (FK-506 alone) 
(Fig. 6). 
Assessment of chimerism. All of the recipients of 
ACI bone marrow treated with ITLD were chimeric 
and exhibited 20% to 80% donor-type erythrocytes 
(Table III). The animals were tested at 2, 4, 7, and 11 
months. The initial level of chimerism in an individual 
animal was maintained throughout its posttransplant 
course (± 10% ). Control Lewis strain rats and Lewis 
362 Hoffman et at. 
recipients of non-T -depleted syngeneic bone marrow 
were not chimeric as assessed by this technique (data not 
shown). 
DISCUSSION 
All forms of nonspecific immunosuppression are as-
sociated with serious toxic side effects. Although immu-
nosuppression with cyclosporine has revolutionized the 
field of transplantation, microbial infections, viral-
associated lymphomas, nephrotoxicity, and hepatotox-
icity are common complications.2, 10, 11 Using mixed 
syngeneic/allogeneic T lymphocyte-depleted bone mar-
row to reconstitute lethally irradiated mice, Ildstad and 
Sachs produced immunocompetent chimerae with spe-
cific hyporeactivity to donor-type skin grafts and con-
cordant rat xenografts.3, 12-14 
In order to establish whether a similar model of mixed 
chimerism in rats would allow for transplanting donor-
type vascularized organ grafts, we have used reconsti-
tution of lethally irradiated Lewis rats with ACI bone 
marrow to induce hematopoietic chimerism. To repro-
ducibly develop stable chimerae and prevent the graft-
versus-host response, the mouse anti-rat pan-T lym-
phocyte monoclonal antibody OX-1915 was used to 
deplete T cells from ACI (donor) bone marrow. 
The monosized beads used as a carrier for the 
T -lymphocyte depletion were initially developed to im-
prove resolution in liquid chromatography. The addi-
tion of magnetite (20% by weight) to the beads allowed 
them to be used for magnetic separation. The surface of 
the bead is partly hydrophobic, allowing antibodies to 
bind by physical adsorption, and partly hydrophilic 
because of the presence of hydroxyl groups, which can 
be chemically activated to covalently bind antibodies. 16 
These beads have been used in a variety of situations, 
including lymphoma cell removal,16 mononuclear cell 
selection,17 and purging of neuroblastoma cells18 from 
bone marrow. 
Using a bead/T-Iymphocyte ratio of 20:1 (assuming 
a bone marrow population of 5% T lymphocytes for the 
bone marrow and 50% for the spleen) a rapid and 
effective depletion of T cells was accomplished with 
minimal nonspecific cell loss. Lower bead/T -cell ratios 
were less effective in depleting T lymphocytes, based on 
the percentage of cells removed as measured by flow cy-
tometry, and the use of larger numbers of beads was 
accompanied by significant nonspecific cell loss. 
Depletion of the donor T lymphocytes was associated 
with the appearance of a stable chimerism without 
evidence of GVHD. As we have described earlier,6 rat 
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bone marrow contains sufficient numbers of mature T 
lymphocytes to induce GVHD across a variety of his-
tocompatibility differences, and transplantation of mar-
row containing T lymphocytes results in fatal acute 
GVHD. Treatment with the immunosuppressive drugs 
CyA and/or FK-506 was not sufficient to prevent the 
high mortality rates, presumably because of immunoin-
competence (drug plus lethal irradiation) or subclinical 
GVHD, when the recipients received bone marrow 
containing T lymphocytes. The animals that received T 
lymphocyte-depleted marrow began normal weight 
gain 1 week later and steadily progressed to 100% of 
their body weight 10 months after reconstitution. Weight 
gain, long-term survival, a healthy appearance, and ab-
sence of GVHD-all are consistent with a functionally 
intact immune system. 
We have not observed any evidence that immuno-
magnetic T-lymphocyte depletion with OX-19 is asso-
ciated with a higher-than-expected failure of the de-
pleted bone marrow to engraft. This complication of 
bone marrow depletion has been observed in mice, dogs, 
and human beings,19 suggesting that differences in the 
types of T -lymphocyte subsets, the number of residual 
T lymphocytes, or NK cells may have an important in-
fluence on the efficiency of bone marrow reconstitution. 
In summary, immunomagnetic T-lymphocyte deple-
tion is a novel technique, rapidly performed in vitro, that 
is nontoxic to the recipient. It is relatively inexpensive 
and is effective with minimal manipulation of the donor 
marrow. This technique allows the production of 
hematopoietic chimerism without GVHD and may 
have important clinical applications for bone marrow 
and solid organ transplantation. 
We appreciate the technical assistance of Judy Wargo, MS, 
and Jo Harnaha, BS. We also thank Donna Ross for 
assistance with the manuscript. 
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DISCUSSION 
Dr. Collin J. Weber (New York, N.Y.). Have you tried 
this with xenografts, that is, xenogeneic marrow into the rat? 
How soon after injecting purified allogeneic marrow can you 
do a graft of, let us say, skin and get it to take? Is it immedi-
ate, or is there a lag phase? 
Dr. Hoffman. We have not done xenografts in our model. 
It has been done by Ildstad and Sachs using mixed syngeneic/ 
xenogeneic bone marrow reconstitution to develop mixed xe-
nogeneic chimerae in a mouse/rat model. Though having but 
a small percentage of donor type cells within the host animal, 
these chimerae accepted skin grafts in 2 to 3 months after bone 
marrow reconstitution. 
Dr. Weber. I would urge you to consider doing that because 
you seem poised to answer an important question: How sta-
ble is a xenochimera? If I understand Dr. Sachs' data 
correctly, most of his murine chimerae did not hold long term. 
Perhaps there is something peculiar to the mouse. If you can 
show it in the rat, it would push us ahead to do it in, let us 
say, primates. 
Dr. Michael A. Grosso (Denver, Colo.). There has been a 
resurgence of the passenger lymphocyte theory in rejection of 
solid organ transplantation. Lymphocytes from the donor 
organ participate not just in graft-versus-host disease but in 
presenting antigens that initiate allograft rejection. Can you 
see any way to apply this technique to T-cell deplete solid 
organs so as to possibly influence allograft rejection? 
Dr. Hoffman (closing). As far as the issue of graft-versus-
host disease, it may not be a matter of just T-cell depletion. 
There may be some interaction with NK cells, and, in addi-
tion to which, in the mixed chimeric model there appears to 
be a null cell population present in the syngeneic component, 
which may inhibit the graft-versus-host reaction. The immu-
nomagnetic beads have not been used in solid organ research 
or in vivo protocols. 
